Definitive Healthcare Corp. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the 2025 Annual Meeting of Stockholders held on June 5, 2025. The record date for the meeting was April 14, 2025, with 107,962,771 shares of Class A common stock and 38,996,613 shares of Class B common stock issued and outstanding.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Stockholders approved three key proposals:
- Proposal 1 (Election of Directors): All three Class I director nominees were elected to serve until the 2028 annual meeting.
- Kevin Coop: 118,235,389 For; 3,440,264 Withheld.
- Jason Krantz: 117,507,136 For; 4,168,517 Withheld.
- Lauren Young: 108,391,016 For; 13,284,637 Withheld.
- Proposal 2 (Ratification of Auditor): Stockholders ratified the selection of Deloitte & Touche LLP as the independent auditor for fiscal year 2025.
- Results: 129,393,656 For; 3,036,651 Against; 163,334 Abstain.
- Proposal 3 (Advisory Vote on Executive Compensation): Stockholders approved the compensation of named executive officers on a non-binding, advisory basis.
- Results: 108,597,111 For; 12,910,917 Against; 167,624 Abstain.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. Detailed descriptions of the proposals are referenced in the definitive proxy statement filed on April 23, 2025.
Key Facts for Investor Verification
- Verify the full text of the April 23, 2025 Proxy Statement for detailed director biographies and executive compensation specifics.
- Note that 10,917,987 broker non-votes were recorded for the director election and executive compensation proposals.
- Confirm the tenure of the newly elected Class I directors, which expires at the 2028 annual meeting.